首页> 外文期刊>Patient Preference and Adherence >Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
【24h】

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

机译:外周作用阿片受体拮抗剂作为慢性阿片类药物治疗非癌性疼痛患者便秘的治疗选择

获取原文
           

摘要

Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.
机译:阿片类药物引起的便秘(OIC)是阿片类药物治疗的普遍且令人困扰的副作用,不能可靠地响应常规泻药的治疗。 OIC可能是限制治疗的不良事件。具有外围作用的μ阿片受体拮抗剂(例如甲基纳曲酮,纳洛西酚和alvimopan)的药物的最新进展为治疗OIC带来了希望,因此将阿片类镇痛的益处扩展到了更多的慢性疼痛患者。尽管有相关的副作用,包括腹痛,但已通过临床测试外周作用的μ阿片受体拮抗剂可改善肠症状,而不会损害疼痛。其他治疗选择包括羟考酮止痛药与纳洛酮的固定剂量联合产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号